Lung cancer and suspected case
Conditions
Interventions
We carry out HADS (Hospital Anxiety and Depression Scale) to a patient of the lung cancer doubt, and having depressive symptom or not is screened. We give mirtazapine 15mg(after 14 days, up to 30mg) t
Sponsors
Kyoto Prefectural University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patient who received written enough explanation about a purpose, a method, the significance of this study with a document agreement.
Exclusion criteria
Exclusion criteria: The patient who could not carry out HADS or was refused. The patient who has a history of the past with hypersensitivity for mirtazapine. The patient with a history of the past with brain disorder (including dementia and Parkinson's disease) of the tissue except the metastasis to brain. The patient with the past of Mental disease medicine treatment except the sleep inducing drug within three months. The patient with severe hepatic dysfunction or renal dysfunction. The patients with the past of suicide consideration or suicide project. The patients who receive medical treatment with heart trouble (myocardial infarction, angina, conduction disorder). The patient with glaucoma or the intraocular pressure sthenia. The patients who receive medical treatment with dysuria. During a pregnant woman, the nursing and the patient who may be pregnant. The patient who takes a monoamine oxidase inhibitor (MAOI) within two weeks. The patient who judged that the examination medical attendant was inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of the total Hospital Anxiety and Depression Scale (HADS) score before and after 4 weeks treatment with mirtazapine. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quick Inventory of Depressive Symptomatology (QIDS-J),Clinical Global Impression of Improvement (CGI).The change of the total HADS score during the observation period in the non-group given mirtazapine. A comparison of HADS in a mirtazapine treatment group and the non-treatment group. | — |
Countries
Japan
Contacts
Public ContactYoshiko Kaneko
Kyoto Prefectural University of Medicine Pulmonary Medicine
Outcome results
None listed